跳至主要内容
临床试验/NCT03130621
NCT03130621Unknown不适用

Screening of Hereditary Upper Gastrointestinal Cancer in China

Peking University1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2017年1月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
500
试验地点
1
主要终点
Pedigree analysis

研究概览

简要总结

Through exploring the specific genetic mutations in the upper gastrointestinal tract tumors with a family history and specific clinical pathological types,we establish a complete family and follow-up system,in order to improve the screening criteria of Chinese hereditary upper gastrointestinal tumors and carry on primary prevention of disease.

研究设计

研究类型
Observational
观察模型
Family Based
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with gastric cancer, esophageal adenocarcinoma, or duodenal adenocarcinoma meet one of the following criteria:
  • age≤35,gastric cancer with special pathological types;
  • age≤50,≥one first-degree relative of a malignant tumor;
  • ≥ two first-degree/second-degree relatives of a malignant tumor,and ≥one first-degree relative;
  • have ≥two types of malignancies,and age ≤50 at the first time of diagnosis;
  • MSI or dMMR of tissue specimen;
  • Patients with esophageal squamous cell carcinomas meet one of the following criteria:
  • ≥ two first-degree/second-degree relatives of a malignant tumor,and ≥one first-degree relative;
  • have ≥two types of malignancies,and age ≤50 at the first time of diagnosis;
  • MSI or dMMR of tissue specimen;

排除标准

  • Patients do not meet one of the inclusion criteria;

结局指标

主要结局

Pedigree analysis

时间窗: In the first phase of the project, we plan to detect 40-50 families in one year. And in the second phase,we will increase the number of predigree to 200. We hope to finish the phase before 2022.3

We plan to analyse the families of patients who met the inclusion criterias through gene detection.

次要结局

  • somatic mutation landscape of hereditary upper gastrointestinal cancer(We plan to accomplish sample collection, sequencing and data analysis before 2022.3)

研究者

发起方
Peking University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Shen Lin

Chief physician

Peking University

研究点 (1)

Loading locations...

相似试验